Nephrology
Systematic review: Among patients with advanced chronic kidney disease and uremic pruritus, gabapentinoids are the most studied treatments and show the greatest reduction in itch scores
13 Dec, 2020 | 23:16h | UTCInterventions for itch in people with advanced chronic kidney disease – Cochrane Library
Commentary: What is the best treatment for itch in people with chronic kidney disease? – Cochrane Library
Supplement: Lupus in the 21st Century
13 Dec, 2020 | 23:13h | UTCHomepage: Lupus in the 21st Century
Editorial: Lupus in the 21st century
- Classifying and diagnosing systemic lupus erythematosus in the 21st century
- New biomarkers in SLE: from bench to bedside
- Treatment targets in SLE: remission and low disease activity state
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
- Lupus nephritis: clinical presentations and outcomes in the 21st century
- The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?
- The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?
- Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Spironolactone use is associated with improved outcomes in patients with heart failure with preserved ejection fraction and concomitant resistant hypertension
8 Dec, 2020 | 07:44h | UTC
Practice recommendations for the management of the most common forms of secondary hypertension, including primary aldosteronism, renovascular hypertension, pheochromocytoma, Cushing’s syndrome, and sleep apnea
26 Nov, 2020 | 08:59h | UTC
Cohort study suggests there is no need to choose first-line drug treatment for hypertension according to age and ethnicity – guidelines could be simplified
26 Nov, 2020 | 08:56h | UTCCommentary: Study questions blood pressure drug guidance based on age and ethnicity – British Medical Journal AND Laurie Tomlinson: Shining a light into medicine’s dusty corners – The BMJ Opinion AND UK’s NICE Guidelines for Hypertension Tx Based on Age, Ethnicity May Need Updating – Physician’s Weekly AND
Commentary on Twitter
Current UK guidance on drug treatment for high blood pressure, which differs depending on a patient’s age and ethnicity, could be simplified in line with other international guidelines, suggests new @bmj_latest research @SarahJoSinnott https://t.co/bWLhXoFnV4
— The BMJ (@bmj_latest) November 21, 2020
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:08h | UTCSotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
KDIGO Guideline Synopsis: Diabetes management in chronic kidney disease. Use of ACE inhibitors or ARBs, glycemic monitoring and targets, and choice of antihyperglycemic drugs are covered
11 Nov, 2020 | 09:09h | UTCOriginal guideline: Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more
5 Nov, 2020 | 08:58h | UTCClinical Management of Hyperkalemia – Mayo Clinic Proceedings
The value of urinary sodium assessment in acute heart failure
3 Nov, 2020 | 03:02h | UTC
Case study: Urinary magnesium in the evaluation of hypomagnesemia
2 Nov, 2020 | 02:19h | UTCUrinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)
KDIGO Controversies Conference on onco-nephrology
30 Oct, 2020 | 01:03h | UTC
Commentary on Twitter
.@goKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer ca. 2020 from @Kidney_Int #Nephpearls#Onconephrology ?
?? https://t.co/u6ANtXdKfy pic.twitter.com/4xJ0gGohoE— Edgar V. Lerma ?? (@edgarvlermamd) October 28, 2020
Randomized trial suggests rapid intermittent bolus of hypertonic saline is the best approach for the treatment of symptomatic hyponatremia
27 Oct, 2020 | 09:36h | UTC
For managing symptomatic #hyponatremia, both rapid intermittent bolus (RIB) and slow continuous infusion of hypertonic saline are safe and effective, but RIB achieves a target serum sodium sooner and needs lesser therapeutic re-lowering of serum sodium https://t.co/J4y4BbA855
— JAMA Internal Medicine (@JAMAInternalMed) October 26, 2020
[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
25 Oct, 2020 | 23:34h | UTCEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive
Commentary on Twitter (thread – click for more)
‼️Effect of Finerenone on CKD outcomes in T2DM
⚡️Finerenone decreased risk of CKD progression by 18%
⚡️Finerenone decreased CV morbidity & mortality by 14%
Published in @NEJM today https://t.co/XvshpZZCK4@ASNKidney #Kidneywk pic.twitter.com/FOkxnG1enz
— Aisha Shaikh (@aishaikh) October 23, 2020
Randomized trial: Effects of regional citrate anticoagulation vs. systemic heparin anticoagulation on dialysis filter life span and mortality among critically ill patients with acute kidney injury
25 Oct, 2020 | 23:32h | UTC
Commentary on Twitter
In this RCT, anticoagulation with regional citrate, compared with systemic heparin, resulted in longer filter life span in patients with acute kidney injury receiving continuous kidney replacement therapy https://t.co/fmkawnqjmM #VisualAbstract
— JAMA (@JAMA_current) October 23, 2020
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
20 Oct, 2020 | 01:33h | UTCExecutive summary: 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment – Kidney International
Commentary on Twitter
2020 #KDIGO Diabetes Management in #CKD Guidelinehttps://t.co/G127PgO1fe@deboerih @P_Rossing @goKDIGO pic.twitter.com/3kVNDpAoub
— Kidney International (@Kidney_Int) October 4, 2020
[Abstract Only] Systematic review and meta-analysis of native kidney biopsy complications
20 Oct, 2020 | 01:26h | UTCSystematic Review and Meta-Analysis of Native Kidney Biopsy Complications – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis found that although native kidney biopsy is an invasive diagnostic procedure, the rates of bleeding complications are low. Complications are more frequently seen after kidney biopsies of hospitalized patients with AKI. https://t.co/kxK6qxX1fc pic.twitter.com/SgCoI505cc
— CJASN (@CJASN) October 15, 2020
[Abstract Only] Meta-analysis: Effect of urate-lowering therapy on cardiovascular and kidney outcomes
20 Oct, 2020 | 01:22h | UTCEffect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Study found urate-lowering therapy didn't produce benefits on clinical outcomes including major adverse cardiovascular events, all-cause mortality & kidney failure. Insufficient evidence to support urate lowering to improve kidney & cardiovascular outcomes https://t.co/uifm4vikYe pic.twitter.com/3fV60V3Lcx
— CJASN (@CJASN) October 14, 2020
Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial
15 Oct, 2020 | 09:00h | UTCCommentaries: A Tale of 2 Blood Pressures – JAMA Internal Medicine AND Real-World BP Measurements vs SPRINT Protocol – Physician’s Weekly
Commentary on Twitter
Incredibly important paper in @JAMAInternalMed demonstrating poor concordance between clinic blood pressure and trial based blood pressure. https://t.co/waLTYk9Lnu
— Stephen Juraschek MD, PhD (@spjuraschek) October 13, 2020
COVID-19 and the kidney
8 Oct, 2020 | 09:02h | UTCCOVID-19 and the kidney – Cleveland Clinic Journal of Medicine
KDOQI clinical practice guideline for nutrition in CKD: 2020 update
6 Oct, 2020 | 00:08h | UTC
AHA Scientific Statement: Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease
29 Sep, 2020 | 10:00h | UTCNews Release: Newer Type 2 diabetes medications have heart and kidney disease benefits, too – AHA Newsroom
Randomized trial: Dapagliflozin in patients with chronic kidney disease
25 Sep, 2020 | 02:34h | UTCDapagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (free for a limited period)
Commentary: Dapagliflozin Cuts Renal Risks in Patients with CKD, Regardless of Diabetes Status – NEJM Journal Watch
JAMA Network Series: Medical Specialties and the COVID-19 Pandemic
24 Sep, 2020 | 09:45h | UTCEditorial: The COVID-19 Pandemic and the JAMA Network
See articles:
- Cardiology and COVID-19
- Dermatology and COVID-19
- Internal Medicine and COVID-19
- Nephrology and COVID-19
- Neurology and COVID-19
- Oncology and COVID-19
- Ophthalmology and COVID-19
- Otolaryngology–Head and Neck Surgery and COVID-19
- Pediatrics and COVID-19
- Psychiatry and COVID-19
- Surgery and COVID-19
- JAMA Network Open and COVID-19
- JAMA Health Forum and COVID-19
[Abstract Only] Two-year, randomized, controlled trial of belimumab in lupus nephritis
17 Sep, 2020 | 09:20h | UTCTwo-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis – New England Journal of Medicine (link to abstract – $ for full-text)
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine